Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Anticipating approval next year of eteplirsen, an RNA-based treatment for Duchenne muscular dystrophy, Sarepta Therapeutics will spend $25 million to acquire and upgrade a former Eisai drug manufacturing facility in Andover, Mass. Sarepta says the Japanese firm built the site in 1996 and upgraded it in 2006. It supports 40 technicians and other staffers when fully operational. In April, Sarepta said it will file a New Drug Application for eteplirsen by the end of this year.
This article has been sent to the following recipient: